Dipna Pharmachem Ltd

Dipna Pharmachem Other Announcement

Dipna Pharmachem Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR, detailing the distribution of equity shares.

Dipna Pharmachem Q4 FY26 Results: Net Profit ₹0.2 Cr, Down 60.0% YoY

Dipna Pharmachem Ltd reported revenue from operations of ₹2.1 Cr (-86.8% YoY) and net profit of ₹0.2 Cr (-60.0% YoY) for Q4 FY26.

Key figure

Net profit ₹0.2 Cr · -60.0% YoY

Dipna Pharmachem Management Change

Dipna Pharmachem appointed two new Independent Directors effective May 11, 2026. Board committees were also reconstituted to enhance governance.

Dipna Pharmachem Board Meeting Date

Dipna Pharmachem scheduled a board meeting for July 1, 2026. The board will review audited half-year and annual financial results.

Dipna Pharmachem Other Announcement

Dipna Pharmachem Limited filed its Annual Secretarial Compliance Report for FY2026. The report notes procedural non-compliances regarding the appointment of a qualified Company Secretary.

Dipna Pharmachem Annual General Meeting

Shareholders approved appointing M/s. Jay Pandya & Associates as Secretarial Auditor for FY 2025-26 via postal ballot. The resolution passed with a 99.77% majority.

Dipna Pharmachem Annual General Meeting

Dipna Pharmachem Limited has published newspaper advertisements confirming the dispatch of postal ballot notices and providing details for remote e-voting. The advertisements appeared in Financial Express (English and Gujarati) on April 24, 2026. This filing is in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations.

Dipna Pharmachem Management Change

Dipna Pharmachem Limited has recommended the appointment of M/s. Jay Pandya & Associates as Secretarial Auditor for FY 2025-26. The Board also approved a postal ballot for member approval via remote e-voting, commencing April 23, 2026.

Execution

Financial Year 2025–26

Dipna Pharmachem Annual General Meeting

Dipna Pharmachem Limited has issued a Postal Ballot Notice to appoint M/s. Jay Pandya & Associates as Secretarial Auditor for FY 2025-26. The remote e-voting period runs from April 23, 2026, to May 22, 2026. This is a routine regulatory procedure to obtain member consent for statutory compliance requirements.

Execution

Financial year 2025-26

Dipna Pharmachem Price Movement Clarification

Dipna Pharmachem Ltd clarified to BSE that it has no undisclosed price-sensitive information explaining recent significant stock price movements. The company maintains that all required disclosures under SEBI regulations have been made and the volatility is purely market-driven.